Brigatinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
CN
  • Monotherapy for ALK-positive locally advanced or metastatic non-small cell lung cancer
Product first approved 2022takedaoncology.com
JP
  • First and second-line therapy for unresectable, advanced or recurrent ALK fusion gene-positive NSCLC
Product first approved 2021takeda.com
EU
  • ALK-positive advanced NSCLC (first previously treated with crizotinib; EPAR now also covers ALK-inhibitor-naive)
Product first approved 2018EMA
CA
  • ALUNBRIG (brigatinib) is indicated:  as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).  as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to an ALK inhibitor (crizotinib). (See 14 CLINICAL TRIALS)
Product first approved 2018Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Non-Small Cell Lung Cancer
Phase 2 (19)
Non-Small Cell Lung Cancer
NCT05200481 · Intergroupe Francophone de Cancerologie Thoracique
2022-05-18 – 2028-10 · Non Small Cell Lung Cancer, ALK Gene Mutation
What this study did
NCT04223596 · Fundación GECP
2020-05-04 – 2026-12-30 · Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
What this study did
NCT04318938 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2020-03-30 – 2026-05-30 · NSCLC
What this study did
NCT03737994 · National Cancer Institute (NCI)
2019-07-25 – 2026-03-17 · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT06522360 · M.D. Anderson Cancer Center
2024-12-11 – 2025-04-17 · Non-small Cell Lung Cancer
What this study did
NCT04074993 · JI-YOUN HAN
2020-05-15 – 2025-03-31 · Non Small Cell Lung Cancer
What this study did
NCT05718297 · ETOP IBCSG Partners Foundation
2024-06-07 – 2024-09-30 · NSCLC, Stage III, ALK-rearrangement
What this study did
NCT03535740 · Ariad Pharmaceuticals
2019-01-31 – 2024-08-21 · ALK-positive Advanced NSCLC
What this study did
NCT03410108 · Takeda
2018-01-29 – 2021-07-28 · ALK-positive Advanced NSCLC
What this study did
NCT02706626 · Criterium, Inc.
2017-03-09 – 2021-04-01 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04374305 · Scott R. Plotkin, MD, PhD
2020-06-20 – 2030-12-01 · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
What this study did
NCT06813079 · University Health Network, Toronto
2025-04-07 – 2028-02-17 · Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor
What this study did
NCT04634110 · University of Colorado, Denver
2020-11-17 – 2022-04-14 · Brain Metastases, Lung Cancer
What this study did
NCT03868423 · Sameek Roychowdhury
2019-03-20 – 2021-12-30 · Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Malignant Solid Neoplasm, ROS1 Fusion Positive, ROS1 Gene Amplification, ROS1 Gene Mutation
What this study did
NCT03719898 · Fox Chase Cancer Center
2018-12-06 – 2020-06-16 · Anaplastic Large Cell Lymphoma, ALK-Positive
What this study did
Phase 1/2 (3)
Non-Small Cell Lung Cancer
NCT01449461 · Ariad Pharmaceuticals
2011-09-20 – 2020-02-18 · Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT04925609 · Princess Maxima Center for Pediatric Oncology
2022-08-18 – 2033-12 · Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor
What this study did
NCT04260009 · Takeda
2020-09-01 – 2025-09-01 · Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
What this study did
Phase 1 (5)
Non-Small Cell Lung Cancer
NCT03707938 · M.D. Anderson Cancer Center
2018-12-18 – 2028-01-28 · Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04227028 · City of Hope Medical Center
2020-03-09 – 2027-03-25 · Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04005144 · University of California, San Francisco
2020-02-25 – 2022-10-01 · ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
What this study did
NCT03420742 · Takeda
2019-06-26 – 2021-04-29 · Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
What this study did
Other / comorbidity
NCT06132867 · Takeda
2023-12-20 – 2024-02-17 · Healthy Volunteers
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Brigatinib: this drugApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
NeladalkibPhase 3Small moleculeALKnot yet gradedNo reviewed efficacy summary in this indication
AQUA07Phase 1Small moleculeALKnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 545 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Brigatinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04223596 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03-25 · NCT04227028 · CT.gov ↗
What to watch
2028 (2)
January 2028 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-28 · NCT03707938 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 2Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, EpendymomaRecruiting
Est. primary completion 2029-12-01 · NCT04374305 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-10-01 · NCT06620835 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 1/2Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid TumorRecruiting
Est. primary completion 2033-12 · NCT04925609 · CT.gov ↗
What to watch

See the full readout calendar ↗